Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 86
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Inhibiting immune checkpoints
Mary L. Disis
University of Washington, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory T cells
Dario A. Vignali
Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Regulatory myeloid cells
Dmitry I. Gabrilovich
The Wistar Institute, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Immunology and Immunotherapy for Non-Immunologists: How Tumors Regulate Immune Responses
Galectins and immune response in cancer
Gabriel A. Rabinovich
Instituto de BiologĂ­a y Medicina Experimental, CONICET, Ciudad de Buenos Aires, Argentina
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Tumor Heterogeneity
Deciphering cancer genome evolution and intra-tumor heterogeneity: The TRACERx Analysis Pipeline
Gareth A Wilson
The Francis Crick Institute, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Detecting mutational signatures in heterogeneous tumors
Ludmil B Alexandrov
Los Alamos National Laboratory, Los Alamos, NM, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Neutral evolution in cancer: Making sense of intra-tumor heterogeneity
Andrea Sottoriva
The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Inferring the clonaldynamics underlying histologically transformed and treatment resistant follicular lymphomas
Fong Chun Chan
BC Cancer Agency Vancouver BC, Vancouver, BC, Canada
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
New Actionable Targets in Malignancies of the Upper Aerodigestive Tract
Whole exome sequencing study of nasopharyngeal and esophageal cancers
H Phillip Koeffler
Cedars-Sinai Medical Center, Los Angeles, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
New Actionable Targets in Malignancies of the Upper Aerodigestive Tract
Comprehensive molecular profiling datasets in head and neck squamous cell cancer
Jennifer Rubin Grandis
University of California, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
New Actionable Targets in Malignancies of the Upper Aerodigestive Tract
What are actionable targets in the management of head and neck squamous cell and nasopharyngeal cancers?
Brigette B. Ma
Chinese Univ. of Hong Kong, Hong Kong, Hong Kong
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Early Clinical Trials of Novel Agents
Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
Scott T Tagawa
Weill Cornell Medicine, New York, NY, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
Jordan D Berlin
Vanderbilt-Ingram Cancer Center, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)
Davide Melisi
University of Verona, Verona, Italy
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
2-hydroxyoleic acid (2-OHOA), a novel activator of sphingomyelin synthase with antitumor activity in refractory glioblastoma: results of the first-in-human dose-escalation (DE) study in patients with advanced solid tumors (AST) and refractory gliomas/glioblastomas
Juanita S Lopez
Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Discussant
Jeffrey R. Infante
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors
Philippe L Bedard
Princess Margaret Cancer Centre, Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/ GDC-0199), in acute myeloid leukemia patients
Brenda J. Chyla
AbbVie, Inc, North Chicago, IL, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Biomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial
Ravindra Uppaluri
Washington University, St. Louis, MO, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
Early Clinical Trials of Novel Agents
Discussant
S Gail Eckhardt
University of Colorado Cancer Center, Aurora, CO, United States
from AACR Annual Meeting 2016 on April 18, 2016 3:00 PM-5:00 PM
From Epidemiology to Clinical and Public Health Impact: A Case-Study of Liver Cancer in the United States
Invited speaker
Tram K. Lam
National Cancer Institute, Rockville, MD, United States
from AACR Annual Meeting 2016 on April 19, 2016 7:00 AM-8:00 AM
Immuno-oncology Clinical Trials II
Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
Paul Nghiem
University of Washington / Fred Hutchinson, Dermatology/Medicine, Seattle, WA, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Immuno-oncology Clinical Trials II
A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Aaron R Hansen
Princess Margaret Cancer Centre, Toronto, ON, Canada
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Immuno-oncology Clinical Trials II
Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors
Jeffrey R Infante
Sarah Cannon Research Institute, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
Immuno-oncology Clinical Trials II
Discussant
Aurelien Marabelle
Stanford Univ., Stanford, CA, United States
from AACR Annual Meeting 2016 on April 19, 2016 10:30 AM-12:15 PM
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 86